• C4 Therapeutics outlined plans to advance cemsidomide, an oral IKZF1/3 degrader, as a potential foundational multiple myeloma therapy across lines.
• Cash runway expected to extend to end of 2028, targeting key clinical readouts across the portfolio before additional financing needs.
• Phase 2 MOMENTUM trial in 4L+ multiple myeloma targets enrollment completion in Q1 2027, with initial ORR data slated for 2H 2027.
• Combination strategy centers on a Phase 1b trial with Pfizer’s elranatamab, with all-cohort data targeted for mid-2027 to support Phase 3 planning.
• Pipeline expansion includes an INN discovery push, with a goal to deliver 3 potential INDs by 2028 alongside potential NDA timing for cemsidomide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. C4 Therapeutics Inc. published the original content used to generate this news brief on June 11, 2026, and is solely responsible for the information contained therein.